PacBio Appoints Mark Van Oene as President and Chief Executive Officer

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its Board of Directors has appointed Mark Van Oene as President and Chief Executive Officer, effective August 5, 2026. Mr. Van Oene, who has served as Chief Operating Officer, succeeds Christian Henry, who has stepped down as President and Chief Executive Officer after six years leading PacBio. Mr. Van Oene has also been appointed to serve on PacBio's Board of Directors, effective August 5, 2026. Mr. Henry will continue to serve on PacBio’s Board of Directors and has agreed to serve as a business advisor to the company at least through the end of 2026, in order to facilitate an orderly transition.

Mr. Van Oene joined PacBio in 2021 as Chief Operating Officer and has played a central role in advancing the company's operational execution, commercial strategy, product development roadmap and clinical application development as well as leading AI-related product improvements and collaborations. During his tenure, he has worked closely with the executive leadership team and Board of Directors to strengthen PacBio's position as a leader in long-read sequencing and to support PacBio’s strategy to expand adoption across research and future clinical applications.